GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gabather AB (OSTO:GABA) » Definitions » Short-Term Debt

Gabather AB (OSTO:GABA) Short-Term Debt : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Gabather AB Short-Term Debt?

Gabather AB's Short-Term Debt for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Gabather AB Short-Term Debt Historical Data

The historical data trend for Gabather AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gabather AB Short-Term Debt Chart

Gabather AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gabather AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gabather AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Gabather AB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Gabather AB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Gabather AB Business Description

Traded in Other Exchanges
N/A
Address
Forskargatan 20J, Byggn 215 N, Sodertalje, SWE, 151 36
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.

Gabather AB Headlines

No Headlines